The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
Credits: None available.
Live Program Date: Wednesday, March 9, 2022
Program Number: 22EL-712
Educational Track: Technical/Clinical
Topic: Patient Transfusion
Intended Audience: Directors, Hospitals, Medical Directors, Physicians, Students (MD, MT, SBB)
(titles and affiliations at the time of the live program)
Director/Moderator: Amit Gokhale, MD, Transfusion Medicine Attending, Texas Children’s Hospital; Assistant Professor, Baylor College of Medicine, Houston, TX
Speakers: Cyril Jacquot, MD, PhD, Medical Director, Hematology Laboratory and Blood Donor Center; Associate Medical Director, Transfusion Medicine and Therapeutic Apheresis, Assistant Professor of Pathology, Assistant Professor of Pediatrics, Children’s National Hospital, George Washington School of Medicine & Health Sciences, Washington, DC; Jennifer L. Chain, PhD, Director, Research & Development, Oklahoma Blood Institute, Oklahoma City, OK
The ongoing availability of a safe blood supply is absolutely essential for health care. Due to circumstances such as increasing demand and an aging donor pool, the likelihood of blood shortage is increasing. The COVID 19 pandemic has also severely affected the blood supply chain. As a result, hospitals have needed to develop strategies to adapt to these blood supply shortages. Mitigation strategies that were proposed included additional criteria for transfusion orders review with more stringent guidelines. Splitting platelet units into 2 doses each were also considered to minimize platelet shortage. A possible solution that has been brought up is to pay donors, especially for platelets, to increase the blood product availability.
With regards to cellular therapy, approximately two-thirds of patients do not have a suitable human leukocyte antigen (HLA)-matched donor in their family and require an alternative donor to proceed with treatment. Unrelated-donor transplants remain the most common donor choice for allogeneic HSCT, and data from the Center for International Blood and Marrow Transplant Research show increasing numbers of unrelated-donor HSCTs performed each year since 2016.
During these unprecedented times, it has been a challenge to recruit blood and cellular therapies donors. This eCast will delve into current challenges faced by blood and cellular therapy donor centers and discuss possible solutions on how to increase recruitment of donors during these trying times.
After participating in this educational activity, participants should be able to:
How to Claim Continuing Education Credit
You must be logged in and own this session in order to post comments.
How to Claim CE Credit